EGFR and non-small cell lung carcinoma: Since an epidermal growth factor receptor (EGFR) activating mutation has been identified as one of the most common gene mutations in lung cancer, EGFR-tyrosine kinase inhibitors (EGFR-TKIs) became first-line molecular targeted therapies for EGFR-mutated NSCLC patients (Network, 2014).